Compass Therapeutics, Inc. (CMPX)

Market Cap	188.68M
Revenue (ttm)	n/a
Net Income (ttm)	-42.49M
Shares Out	127.49M
EPS (ttm)	-0.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	467,344
Open	1.420
Previous Close	1.480
Day's Range	1.330 - 1.480
52-Week Range	1.150 - 3.620
Beta	0.60
Analysts	Strong Buy
Price Target	9.00 (+516.44%)
Earnings Date	May 2, 2024

About CMPX

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 32
• Stock Exchange: NASDAQ
• Ticker Symbol: CMPX

Analyst Forecast

According to 2 analysts, the average rating for CMPX stock is "Strong Buy." The 12-month stock price forecast is $9.0, which is an increase of 516.44% from the latest price.

Price Target

$9.0

(516.44% upside)

Analyst Consensus: Strong Buy